Agenus Announces Peer-Reviewed Publication Linking BOT+BAL’s Durable Survival in MSS Metastatic Colorectal Cancer to Its Distinct Immune-Priming Mechanism
Go back to Agenus Announces Peer-Reviewed Publication Linking BOT+BAL’s Durable Survival in MSS Metastatic Colorectal Cancer to Its Distinct Immune-Priming Mechanism| AGENUS (NASDAQ: AGEN) | Delayed: 8.24 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $8.24 | 52 Week High | $7.49 | |||
| Open | $8.24 | 52 Week Low | $2.61 | |||
| Day High | $8.24 | P/E | N/A | |||
| Day Low | $8.24 | EPS | $-1.10 | |||
| Volume | 8,600 | |||||
